Major Depressive Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Major Depressive Disorder stocks.

Major Depressive Disorder Stocks Recent News

Date Stock Title
May 16 PFE UPDATE 1-Pfizer offers up to $250 mln to settle Zantac cancer lawsuits, FT reports
May 16 PFE Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
May 15 PFE Dividend picks by SA analysts: PFE, DVN, SBUX and LOW
May 15 ABVC Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
May 15 PFE Pfizer: Best Trading Momentum Since 2021 And 6% Yield
May 15 RVPH Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
May 15 PFE 3 No-Brainer Stocks to Buy With $500 Right Now
May 14 RVPH Reviva Pharmaceuticals GAAP EPS of -$0.25
May 14 PFE 2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
May 14 RVPH Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14 PRAX We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
May 14 PFE NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
May 14 AZN PRESS DIGEST-British Business - May 14
May 13 PFE Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
May 13 AZN UK pharma giants pledge £430m investment in France after Macron charm offensive
May 13 PFE AstraZeneca, Pfizer to invest combined $900M+ in France for R&D, production
May 13 AZN AstraZeneca, Pfizer to invest combined $900M+ in France for R&D, production
May 13 AZN Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study
May 13 PFE One stock is dragging down the S&P 500's earnings growth
May 13 AZN Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Major Depressive Disorder

Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause. People may also occasionally have false beliefs or see or hear things that others cannot. Some people have periods of depression separated by years in which they are normal, while others nearly always have symptoms present. Major depressive disorder can negatively affect a person's personal life, work life, or education, as well as sleeping, eating habits, and general health. Between 2–8% of adults with major depression die by suicide, and about 50% of people who die by suicide had depression or another mood disorder.The cause is believed to be a combination of genetic, environmental, and psychological factors. Risk factors include a family history of the condition, major life changes, certain medications, chronic health problems, and substance abuse. About 40% of the risk appears to be related to genetics. The diagnosis of major depressive disorder is based on the person's reported experiences and a mental status examination. There is no laboratory test for major depression. Testing, however, may be done to rule out physical conditions that can cause similar symptoms. Major depression is more severe and lasts longer than sadness, which is a normal part of life. The United States Preventive Services Task Force (USPSTF) recommends screening for depression among those over the age 12, while a prior Cochrane review found that the routine use of screening questionnaires have little effect on detection or treatment.Typically, people are treated with counseling and antidepressant medication. Medication appears to be effective, but the effect may only be significant in the most severely depressed. It is unclear whether medications affect the risk of suicide. Types of counseling used include cognitive behavioral therapy (CBT) and interpersonal therapy. If other measures are not effective, electroconvulsive therapy (ECT) may be considered. Hospitalization may be necessary in cases with a risk of harm to self and may occasionally occur against a person's wishes.Major depressive disorder affected approximately 216 million people (3% of the world's population) in 2015. The percentage of people who are affected at one point in their life varies from 7% in Japan to 21% in France. Lifetime rates are higher in the developed world (15%) compared to the developing world (11%). It causes the second most years lived with disability, after lower back pain. The most common time of onset is in a person's 20s and 30s. Females are affected about twice as often as males. The American Psychiatric Association added "major depressive disorder" to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980. It was a split of the previous depressive neurosis in the DSM-II, which also encompassed the conditions now known as dysthymia and adjustment disorder with depressed mood. Those currently or previously affected may be stigmatized.

Browse All Tags